Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


 Company News
Pharmacyclics (PCYC) Release: In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3/2/2015 6:51:04 AM
Market Analysis: Pharmacyclics (PCYC) Sale Good Idea if Buyer Understands Imbruvica Potential, Says Analyst 2/26/2015 3:14:26 PM
Bay Area's Pharmacyclics (PCYC) Mulls Possible $18 Billion Sale; Johnson & Johnson (JNJ),Novartis AG (NVS) Interested 2/26/2015 5:53:26 AM
Pharmacyclics, Inc. (PCYC) Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Business Updates 2/18/2015 2:35:11 PM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Treatment Shows Efficacy And Tolerability In Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant 2/17/2015 8:50:05 AM
Pharmacyclics, Inc. (PCYC) Announces Conference Call To Discuss Fourth Quarter And Full Year 2014 Financial Results 2/12/2015 10:35:03 AM
Pharmacyclics, Inc. (PCYC) Announces Preliminary 2014 U.S. Net Product Revenue Results And 2015 U.S. Net Product Revenue Outlook 1/13/2015 9:50:40 AM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy In Previously Untreated And Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients 1/5/2015 7:29:12 AM
Pharmacyclics, Inc. (PCYC) Announces Update On IMBRUVICA® (Ibrutinib) Waldenstrom's Macroglobulinemia (WM) Submission 12/22/2014 8:19:16 AM
Pharmacyclics, Inc. (PCYC) Named 2014 Outstanding Company By BayBio (Bay Area Bioscience Association) 12/12/2014 8:23:38 AM